Akebia Ther (AKBA) - Stock Price & Dividends
Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US00972D1054
Kidney disease treatments, Anemia treatment, Iron supplements
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts. Web URL: https://www.akebia.com
Drawdown (Underwater) Chart
Overall Trend and Yearly Seasonality
AKBA Stock Overview
Market Cap in USD | 272m |
Sector | Healthcare |
Industry | Biotechnology |
GiC SubIndustry | Biotechnology |
TER | 0.00% |
IPO / Inception | 2014-03-20 |
AKBA Stock Ratings
Growth 5y | -3.95 |
Fundamental | -80.9 |
Dividend | - |
Rel. Performance vs Sector | 0.65 |
Analysts | 4.33/5 |
Fair Price Momentum | 1.11 USD |
Fair Price DCF | - |
AKBA Dividends
Yield 12m | 0.00% |
Yield on Cost 5y | 0.00% |
Dividends CAGR 5y | 0.00% |
Payout Consistency | 0.0% |
AKBA Growth Ratios
Growth 12m | 4.42% |
Growth Correlation 12m | 29% |
Growth Correlation 3m | -41% |
CAGR 5y | -26.19% |
CAGR/Mean DD 5y | -0.38 |
Sharpe Ratio 12m | -0.01 |
Alpha vs SP500 12m | -39.08 |
Beta vs SP500 5y weekly | 1.58 |
ValueRay RSI | 10.58 |
Volatility GJR Garch 1y | 93.87% |
Price / SMA 50 | -22.37% |
Price / SMA 200 | -10.61% |
Current Volume | 3627.7k |
Average Volume 20d | 2981.8k |
External Links for AKBA Stock
News
Wall Street Journal • Benzinga • Yahoo Finance
Tweets
X • Stocktwits
Fund Manager Positions
Dataroma • Stockcircle
Wall Street Journal • Benzinga • Yahoo Finance
Tweets
X • Stocktwits
Fund Manager Positions
Dataroma • Stockcircle
What is the price of AKBA stocks?
As of May 16, 2024, the stock is trading at USD 1.18 with a total of 3,627,682 shares traded.
Over the past week, the price has changed by -15.71%, over one month by -15.11%, over three months by -19.73% and over the past year by +8.26%.
As of May 16, 2024, the stock is trading at USD 1.18 with a total of 3,627,682 shares traded.
Over the past week, the price has changed by -15.71%, over one month by -15.11%, over three months by -19.73% and over the past year by +8.26%.
What is the forecast for AKBA stock price target?
According to ValueRays Forecast Model, AKBA Akebia Ther will be worth about 1.3 in May 2025. The stock is currently trading at 1.18. This means that the stock has a potential upside of +5.93%.
According to ValueRays Forecast Model, AKBA Akebia Ther will be worth about 1.3 in May 2025. The stock is currently trading at 1.18. This means that the stock has a potential upside of +5.93%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 5 | 324 |
Analysts Target Price | 3.9 | 229 |
ValueRay Target Price | 1.3 | 5.93 |